Skip to content

Identification of Psychoactive Substance Users in Young Adults (16 to 25 Years Old) Visiting the Emergency Department

Systematic Screening and Identification of Psychoactive Substances Users in Young Adults (16 to 25 Years Old) Visiting the Emergency Department

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04173546
Acronym
DRUGS
Enrollment
459
Registered
2019-11-22
Start date
2020-02-11
Completion date
2021-04-15
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Use, Psychiatric Emergency

Brief summary

Adolescence is a time for great physical and psychological change and it's often at that period of life that first use of psychoactive substances occurs. Although addiction is rare in teenagers, psychoactive substances abuse can have serious long-term health consequences on them. This is therefore a priority for all healthcare providers to identify early use and abuse of drugs in the youth's population. The addictive process underlies environmental, genetic and individual causes. That is why it is somehow possible to identify individuals at risk based on some common sociological, cultural and environmental risk factors. Due to the acute consequences of psychoactive substances abuses, Emergency Departments are main checkpoints for the screening of young drug users. Indeed, one patient out of five admitted in an Emergency Department shows a positive blood alcohol concentration regardless of the reason for their admission. This rate is twice as high as in the overall population. Hence, Emergency Departments are at the front-line for screening, caring, referral and transfer of psychoactive substances users. That is why the Emergency Department is the best place for this study. In 2004, the special consultations of young consumers were founded in order to deal with these special cases where dependence is not yet established or installed and care has to be adapted to the age. Offering help to this age range represents a real challenge since only 20% of the teenagers come to visit this special consultations on their own initiative. The rest of teenagers are either obliged by their parents or sentenced by a court. The investigators assume that the repetition of care offered to the teenagers by repeated emergency admissions could trigger their own desire to overcome their drug use disorders and visit the Addictionology Department.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* All patients aged 16 to 25 admitted at the Medical and Psychiatric Emergency Department. * For adults: those who will agree to participate in this study * For Minors from the age of 16: those who will agree to participate and want to exercise their rights by themselves or for whom one parent or legal guardian agrees for their participation.

Exclusion criteria

* patient who doesn't understand French * patient under legal protection measures or guardianship * confused person (GSC \< 15)

Design outcomes

Primary

MeasureTime frameDescription
Consumption questionnaire and urinary strips to detect psychoactive substances usersFollow-up time: 3 monthsThe primary objective of the study is to evaluate the prevalence of psychoactive substances use among young adults, aged 16 to 25, visiting the Emergency Department. This evaluation will be twofold: * declarative through a consumption questionnaire (response by Yes or No without score) (whole life, past three months and previous month) * analytical by means of a urinary screening for recent consumptions (from a few days to a few weeks according to the products) of seven psychoactive substances (Alcohol, tobacco, cannabis, ecstasy, amphetamines, cocaine, morphinics).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026